Babintseva Ya D, Camont L, Chapman J, Lhomme M, Karagodin V P, Kontush A, Orekhov A N
Institute of General Pathology and Pathophysiology, Moscow, Russia.
French National Institute of Health and Medical Research, 1166 ICAN, Hôpital de la Pitié-Salpêtrière, Pierre and Marie Curie University, Paris, France.
Ter Arkh. 2016;88(9):111-118. doi: 10.17116/terarkh2016889111-118.
Increasing the human plasma concentration of high-density lipoproteins (HDL) may be part of strategy for control of cardiovascular diseases (CVD). HDL particles vary in their structure, metabolism, and biological activity. The review describes major HDL fractions (subpopulations) and discusses new findings on the antiatherogenic properties of HDL particles. The whole spectrum of HDL fractions, small, dense, protein-rich lipoproteins, has atheroprotective properties that are determined by the presence of specialized groups of proteins and lipids; however, this activity may be decreased in atherogenic lesion. Comprehensive structural and compositional analysis of HDL may provide key information to identify the fractions that have characteristic biological properties and lose their functionality in CVD. These fractions may be also biomarkers for the risk of CVD and hence represent pharmacological targets.
提高人体血浆中高密度脂蛋白（HDL）的浓度可能是控制心血管疾病（CVD）策略的一部分。HDL颗粒在结构、代谢和生物活性方面存在差异。本文综述描述了主要的HDL组分（亚群），并讨论了HDL颗粒抗动脉粥样硬化特性的新发现。HDL组分的整个谱系，即小而致密、富含蛋白质的脂蛋白，具有由特定蛋白质和脂质组决定的抗动脉粥样硬化特性；然而，这种活性在动脉粥样硬化病变中可能会降低。对HDL进行全面的结构和成分分析，可能会提供关键信息，以识别具有特征性生物学特性且在CVD中丧失功能的组分。这些组分也可能是CVD风险的生物标志物，因此代表了药理学靶点。
